DRUG
kisspeptin 112-121
SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
Status
Recruiting
Phase
Phase 2
Enrollment
36
Locations
1
Results
Not posted
Publications
0
Study summary
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in men and women with idiopathic hypogonadotropic hypogonadism (IHH). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered SC for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth (for women) and frequent blood sampling (every 10 minutes for up to 70 minutes) will be performed to assess the physiologic response to kisspeptin over time. Funding Source: FDA OOPD
Assignment: All study subjects will undergo the same interventions. Delivery of Interventions: * Each subject will undergo a review of their medical history, physical exam, and screening laboratories. * A single SC injection of leuprolide acetate may be administered approximately six days before kisspeptin administration. (Previously administration of Gonadotropin Releasing Hormone (GnRH) was used in this study.) * A pelvic ultrasound will be performed on women to assess baseline follicular size. * A pump will be placed to administer pulsatile SC kisspeptin for two weeks. * During the course of kisspeptin administration, subjects will * Undergo q10 min blood sampling (approximately 10 sessions, 70 minutes each) * For women, undergo pelvic ultrasounds (approximately 4 sessions) * Optional q10 min sampling up to 8 hours may take place before and after the course of kisspeptin
Interventions
DRUG
SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
DRUG
Single SC bolus
Timeline
First posted
Jun 9, 2023
Study start
Feb 3, 2023
Primary completion
May 2028
Study completion
May 2028
Results posted
Not reported
Registry updated
Jul 13, 2026
Outcomes
Average change in luteinizing hormone (LH) pulse amplitude
Time frame · 2 weeks
Average difference in LH amplitude after the first dose of kisspeptin (day 1) compared to the last dose of kisspeptin (day 15)
Percentage of female participants who demonstrate achievement of a mature follicle or show evidence of ovulation
Time frame · 2 weeks
Percentage of female participants that develop a mature follicle or ovulate. Mature follicle achievement is defined as evidence of a follicle with maximum diameter ≥18 mm. Evidence of ovulation is defined as detection of a corpus luteum on ultrasound in combination with elevated progesterone level.
Eligibility
Inclusion Criteria: * Congenital IHH * Confirmed diagnosis by medical provider supported by low sex steroids in the setting of low or inappropriately normal gonadotropins * Normal blood pressure (systolic BP \< 140 mm Hg, diastolic \< 90 mm Hg) * No current or recent use of a medication that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and method of administration * If applicable, willing to use birth control methods (as approved by a study medical professional) during the entire study and for one month after the last dose of study drug Exclusion Criteria: * Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol * Excessive alcohol consumption (\>10 drinks/week) * Active use of illicit drugs (not including marijuana) * For women: * Pregnant or trying to become pregnant * Breast feeding * History of: bilateral oophorectomy (both ovaries were removed), breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or undiagnosed abnormal genital bleeding
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
Massachusetts General Hospital
Boston, Massachusetts, United States
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Astellas Pharma Global Development, Inc. · Prostate Cancer
Phase 2
Recruiting
900
2026-07
National Cancer Institute (NCI) · Locally Advanced Salivary Gland Carcinoma · Metastatic Salivary Gland Carcinoma
Phase 2
Active, not recruiting
21
2026-07
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Systemic Lupus Erythematosus (Sle) · Primary Ovarian Insufficiency (Poi)
Not applicable
Recruiting
100
2026-07
Dana-Farber Cancer Institute · Prostate Cancer · Prostatic Neoplasms
Phase 2
Recruiting
110
2026-07
LG Chem · Central Precocious Puberty
Phase 4
Recruiting
43
2026-07
ECOG-ACRIN Cancer Research Group · Prostate Carcinoma
Phase 3
Active, not recruiting
27
2026-07
National Cancer Institute (NCI) · Adult Ovarian Granulosa Cell Tumor
Phase 2
Active, not recruiting
17
2026-07
RenJi Hospital · Prostate Cancer · Prostate
Phase 2
Not yet recruiting
200
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.